Mylan CEO defends EpiPen price hike in congressional hearing
The fight over the price of the EpiPen, an emergency treatment device for severe allergic reactions, has officially reached Capitol Hill. CEO Heather Bresch of Mylan, the company that makes the EpiPen, defended the drug's drastic price increase during a congressional hearing Wednesday as a balance between "price and access," pointing out that Mylan only profits $50 for each two-pack sold and that it has in the past distributed EpiPens to schools for free.
Читать дальше...